Advertisement

Induction of Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia Cells

  • J. V. Teichmann
  • W.-D. Ludwig
  • H. Seibt-Jung
  • G. Sieber
  • E. Thiel
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 32)

Abstract

Lymphokine-activated killer (LAK) cells are known to lyse fresh solid tumor cells in vitro [1], and clinical studies suggest that adoptive immunotherapy with LAK cells and interleukin-2 (IL-2) may be a promising approach in the treatment of solid tumors [2, 3]. As only few data are available on the LAK cell system in connection with human leukemia [4, 5], we investigated the induction of LAK cells against human leukemia cells in vitro and studied the augmentation of cytotoxic mechanisms which may be achieved by the combined application of different lymphokines or the coculturing of effector cells with tumor cells.

Keywords

Human Leukemia Cell Adoptive Immunotherapy Acute Myeloblastic Leukemia Specific Lysis Daudi Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841PubMedCrossRefGoogle Scholar
  2. 2.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and in- terleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897PubMedCrossRefGoogle Scholar
  3. 3.
    West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905PubMedCrossRefGoogle Scholar
  4. 4.
    Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986) Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68: 938–948PubMedGoogle Scholar
  5. 5.
    Lotzovâ E, Savary CA, Herberman RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 138: 2718–2727PubMedGoogle Scholar
  6. 6.
    Ludwig W-D, Bartram CR, Ritter J, Raghavachar A, Hiddemann W, Heil G, Harbott J, Seibt-Jung H, Teichmann JV, Riehm H (1988) Abiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multi-parameter analysis. Blood 71: 1518–1528PubMedGoogle Scholar
  7. 7.
    Lotzovâ E, Savary CA, Herberman RB, Dicke KA (1986) Can NK cells play a role in therapy of leukemia? Nat Immun Cell Growth Regul 5: 61–63PubMedGoogle Scholar
  8. 8.
    Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin-2 expanded tumor-in-filtrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48: 206–214PubMedGoogle Scholar
  9. 9.
    Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai K (1985) Generation of activated killer (AK) cells by recombinant in- terleukin-2 (rIL-2) in collaboration with interferon-gamma ( IFN-y ). J Immunol 134: 3124–3129PubMedGoogle Scholar
  10. 10.
    Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G (1987) Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B-lymphoblastoid cell lines. Nat Immun Cell Growth Regul 6: 171–188PubMedGoogle Scholar
  11. 11.
    Phillips JH, Lanier LL (1985) A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K 562. J Exp Med 161: 1464–1482PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. V. Teichmann
    • 1
  • W.-D. Ludwig
    • 1
  • H. Seibt-Jung
    • 1
  • G. Sieber
    • 1
  • E. Thiel
    • 1
  1. 1.Dept. of Hematology and Oncology, Klinikum SteglitzFree University of BerlinGermany

Personalised recommendations